Tag:
Paul Bisaro
Latest Headlines
Latest Headlines
Is Watson poised to grab Actavis?
The generic world was abuzz yesterday after rumors surfaced that Watson Pharmaceuticals could buy Actavis for about $7 billion.
Watson chief has big brand plans for $6B war chest
Paul Bisaro has made no secret of his branded ambitions for Watson Pharmaceuticals ( $WPI ). The drugmaker, which now focuses mostly on generics, is looking to remake itself as a brand-and-generics
Watson wins regulatory OK for Rapaflo
Watson Pharmaceuticals scored a victory in its effort to branch out of its generic drug business and launch new branded therapies with today's announcement that it has won regulatory approval to
